We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+25.82%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$11.2M
Cap. Flow
+$16.6M
Cap. Flow %
9.07%
Top 10 Hldgs %
33.05%
Holding
110
New
26
Increased
27
Reduced
30
Closed
19

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$9.45M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.59M
3
MRUS
Merus
MRUS
+$5.65M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$5.12M
5
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.14M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$7.21M
2
EPIX
ESSA Pharma
EPIX
+$5.8M
3
DCTH icon
Delcath Systems
DCTH
+$5.74M
4
STRO icon
Sutro Biopharma
STRO
+$4.02M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 91.04%
2 Miscellaneous 4.89%
3 Financials 3.11%
4 Industrials 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$885M
$8.49M 4.63%
+336,737
New +$6.59M
CRIS icon
2
Curis
CRIS
$3.61M
$7.12M 3.88%
1,572
+247
+19% +$1.03M
VCEL icon
3
Vericel Corp
VCEL
$2.1B
$6.78M 3.7%
122,125
-159,221
-57% -$7.21M
INSM icon
4
Insmed
INSM
$25.9B
$6.5M 3.54%
190,810
+15,810
+9% +$604K
AMYT
5
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$5.99M 3.27%
429,863
+27,307
+7% +$382K
IMGN
6
DELISTED
Immunogen Inc
IMGN
$5.91M 3.22%
729,364
+129,364
+22% +$1.06M
RACB
7
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.13M 2.8%
+500,000
New +$5.12M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.11M 2.79%
200,000
-27,388
-12% -$700K
MRUS
9
DELISTED
Merus
MRUS
$5.11M 2.79%
+244,713
New +$5.65M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.46M 2.43%
48,476
+18,476
+62% +$1.56M
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.42M 2.41%
130,117
-69,883
-35% -$2.42M
HALO icon
12
Halozyme
HALO
$12B
$4.38M 2.39%
104,945
+4,945
+5% +$226K
MSACU
13
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
$4.01M 2.19%
+406,791
New +$4.14M
AFMD
14
DELISTED
Affimed
AFMD
$3.97M 2.17%
50,233
+10,233
+26% +$664K
ALDX icon
15
Aldeyra Therapeutics
ALDX
$89.9M
$3.82M 2.09%
+321,879
New +$3.71M
MORF
16
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.8M 2.07%
60,000
+8,567
+17% +$393K
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.6M 1.96%
350,000
-56,665
-14% -$621K
RNLX
18
DELISTED
Renalytix plc American Depositary Shares
RNLX
$3.45M 1.88%
134,555
-6,698
-5% -$168K
TCRR
19
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.43M 1.87%
155,145
+19,145
+14% +$522K
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.42M 1.87%
50,089
+33,589
+204% +$2.72M
VCYT icon
21
Veracyte
VCYT
$3.48B
$3.23M 1.76%
+60,000
New +$3.46M
EYPT icon
22
EyePoint Inc
EYPT
$386M
$3.05M 1.66%
+300,000
New +$3.38M
VSTM icon
23
Verastem
VSTM
$654M
$2.96M 1.61%
99,791
+5,145
+5% +$144K
DCOY
24
Decoy Therapeutics
DCOY
$1.9M
$2.95M 1.61%
+55
New +$3.15M
CCXI
25
DELISTED
ChemoCentryx, Inc.
CCXI
$2.87M 1.56%
55,974
+2,208
+4% +$133K
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Silverarc Capital Management held 110 positions worth $183M, up 6.5% from $172M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management deployed $16.6M of net new capital in Q1 2021, opening 26 new positions and adding to 27 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Vericel Corp, an estimated $7.21M trimmed.

  • Silverarc Capital Management's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
  • Silverarc Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021, an estimated $2.72M increase.
  • Silverarc Capital Management's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $7.21M.
  • Silverarc Capital Management fully exited Sutro Biopharma in Q1 2021, selling an estimated $4.02M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $183M portfolio in Q1 2021.
  • Silverarc Capital Management opened 26 new positions and closed 19 in Q1 2021.
  • Silverarc Capital Management's portfolio value rose 6.5% quarter-over-quarter to $183M.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.